Sophiris Bio Inc SPHS

Healthcare Biotechnology

Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.

EXPM:SPHS - Post by User

Sophiris Bio Inc

Bullboard Posts

Comment by sandufon Jan 07, 2015 4:03pm

86 Views

Post# 23295589

RE:What the heck?

I am still tempted to hang in there and maybe grab another TFSA lot while it is in the tank. I still haven't seen any recommendations to "sell". Lots to "hold" and others to "buy".

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale